PRTN3 and rheumatoid arthritis: Likewise, Hodkinson et al. [45], Verschueren et al. [108], Vázquez et al. [27], Boire et al. [109], da Mota et al. [84] and Gossec et al. [70] found no association between ACPA status and the likelihood of achieving low disease activity or remission at 1, 2, 2.5, 3 or 5 years in DMARD-naïve early RA patients treated with MTX and/or other DMARDs.